Status:
UNKNOWN
Glycocalyx Biomarkers in ARDS for Clinical Prognosis and Pulmonary Fibrosis
Lead Sponsor:
Southeast University, China
Conditions:
ARDS, Human
Endothelial Dysfunction
Eligibility:
All Genders
18-80 years
Brief Summary
ARDS is a severe disease in ICU, and could induce high mortality. Glycocalyx is an important matrix construction which covers endothelial cells, it could protect endothelial cells injury and the glyco...
Eligibility Criteria
Inclusion
- Age \> 18yrs and \<80yrs
- Meet ARDS Berlin definition
- With mechanical ventilation
Exclusion
- have chronic pulmonary disease
- have use heparin or low molecular heparin or chondroitin sulfuric acid
Key Trial Info
Start Date :
May 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2019
Estimated Enrollment :
336 Patients enrolled
Trial Details
Trial ID
NCT03854565
Start Date
May 1 2019
End Date
December 31 2019
Last Update
February 26 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongda Hospital, Southeast University
Nanjing, Jiangsu, China, 210009